On September 12, 2022 Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, reported that highlights from the company’s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022, in Austin, Texas (Press release, Quince Therapeutics, SEP 12, 2022, View Source [SID1234619464]). At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company’s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Stewart Low, Quince’s head of discovery, said, "Supported by more than 10 years of extensive preclinical studies, we believe Quince’s proprietary bone-targeting platform can be harnessed to enable the precise delivery of drug concentrated directly to the site of bone injury and disease to accelerate healing. We are excited to continue to bring our preclinical research forward to demonstrate the potential of our proprietary targeting platform with additional indications in spinal fusion and bone cancer as we seek to improve outcomes in underserved patient populations."
ASBMR 2022 Poster Highlights
The following are highlights from the company’s poster presentations of preclinical data exploring spinal fusion and bone cancer indications at ASBMR 2022:
Poster: Improved Spinal Fusion Through Targeted Delivery of Abaloparatide
With more than 400,000 spinal fusions performed in the U.S. every year, Quince believes there is an opportunity to utilize its bone-targeting platform to improve patient outcomes in spinal fusion with its NOV004 targeted therapeutic.
Quince developed a bone-targeting compound based on acidic oligopeptides which is designed to stimulate bone growth at spinal fusion sites.
In preclinical studies, NOV004 concentrated at spinal fusion sites to demonstrate accelerated repair in treated animals which resulted in significantly improved blinded radiographic fusion scores compared to animals treated with the current standard of care, bone morphogenic protein-2 (BMP-2).
In addition, NOV004’s subcutaneous administration would allow for repeat dosing post operatively compared to current spinal fusion strategies that generally require surgery to apply the drug and only allow for one application.
Poster: Evaluating the Efficacy of an Acidic Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver Radioactive Agents to Bone Cancers
With five-year survival rates of less than 20% to 30% in patients with breast and prostate cancer related bone metastases, Quince believes there is an opportunity to utilize its bone-targeting platform to develop targeted radiotherapeutics to improve patient outcomes in breast and bone cancer related bone tumor growth.
Quince developed a radioactive acidic oligopeptide conjugate to target and deliver imaging and therapeutic agents with high tumor-bearing bone specificity.
In preclinical studies, the company confirmed that its targeting moiety can localize to metastatic tumor sites in both osteolytic and osteoblastic lesions and can selectively deliver both fluorescent dye and radioisotope-chelated agents without obvious offsite localization.
In addition to demonstrating rapid renal excretion, the radioactive conjugates were retained in the diseased bone even at two weeks post injection.
To view the posters presented at ASBMR 2022, please visit the Science section of Quince’s corporate website.